Kissei Pharmaceutical Co (JP:4547) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kissei Pharmaceutical Co. has secured exclusive rights to develop and commercialize the acute myeloid leukemia drug ‘olutasidenib’ in Japan, South Korea, and Taiwan from Rigel Pharmaceuticals. Olutasidenib, which was approved in the US in December 2022, works by restoring normal cell differentiation by targeting IDH1 gene mutations in adult patients with relapsed or refractory AML. This strategic move is expected to enhance Kissei’s portfolio in treating rare diseases and meet the high unmet medical needs in these regions.
For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.